• 2014/9/24
• Status: Announced
• Deal type: M&A

Well-placed sources indicated that Guo has been deeply involved in pharmaceutical price management for many years, and the investigation may put mean delays to this year's Traditional Chinese Medicine (TCM) price adjustment implementation. Guo has been a vocal driver of the NDRC's current reform efforts focused on the drug price formulation mechanism, which in recent months have seen the Commission successively free up pricing for low-priced drugs, medical service fees and OTC prices. The Department of Price's potential implication in corruption investigations and accompanying impact on human resources will mean that future drug reforms are likely to be affected.

2014-10-10 update Chinese conglomerate Fosun International Ltd., owner of Shanghai Fosun Pharmaceutical , (SHA: 600196) has raised its offer for Portuguese hospital group Espirito Santo Saude (ESS) to EUR 5.01 (USD 6.33) per share from EUR 4.82 (USD 6.09), above U.S. firm United Health's offer of EUR 5 made directly to the bankrupt Espirito Santo family. Portugal's market regulator extended the deadline for investors to accept or refuse Fosun's offer by four days to October 14.